David A Reardon Selected Research

Epitopes

1/2019	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
1/2018	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
1/2018	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Reardon Research Topics

Disease

174	Glioblastoma (Glioblastoma Multiforme) 01/2024 - 01/2004
164	Neoplasms (Cancer) 01/2024 - 05/2002
92	Glioma (Gliomas) 11/2023 - 03/2002
41	Brain Neoplasms (Brain Tumor) 12/2023 - 10/2003
11	Disease Progression 08/2023 - 01/2012
11	Meningioma (Meningiomas) 01/2022 - 01/2012
10	Melanoma (Melanoma, Malignant) 01/2023 - 04/2006
9	Fatigue 10/2019 - 12/2010
7	Lymphopenia (Lymphocytopenia) 04/2024 - 06/2010
5	Edema (Dropsy) 01/2023 - 02/2017
5	Astrocytoma (Pilocytic Astrocytoma) 10/2019 - 01/2006
5	Hemorrhage 01/2018 - 10/2009
5	Diarrhea 01/2018 - 01/2004
4	Neoplasm Metastasis (Metastasis) 10/2023 - 08/2018
4	Oligodendroglioma 05/2022 - 01/2006
4	Residual Neoplasm 10/2019 - 11/2010
4	Thrombocytopenia (Thrombopenia) 09/2014 - 04/2003
3	Pituitary Neoplasms (Pituitary Adenoma) 10/2023 - 06/2016
3	Hypoxia (Hypoxemia) 01/2021 - 12/2010
3	Gliosarcoma 01/2020 - 01/2006
3	Hypertension (High Blood Pressure) 10/2019 - 01/2013
3	Lymphoma (Lymphomas) 01/2014 - 01/2013
2	Seizures (Absence Seizure) 01/2024 - 04/2015

Drug/Important Bio-Agent (IBA)

62	Temozolomide (Temodar)FDA LinkGeneric 01/2024 - 02/2003
54	Bevacizumab (Avastin)FDA Link 01/2024 - 02/2007
28	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2004
21	Immune Checkpoint InhibitorsIBA 01/2024 - 09/2015
21	Monoclonal AntibodiesIBA 01/2022 - 03/2002
20	Biomarkers (Surrogate Marker)IBA 01/2024 - 02/2011
19	VaccinesIBA 01/2023 - 05/2008
19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2008
18	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 05/2003
15	epidermal growth factor receptor VIIIIBA 01/2022 - 10/2009
14	Proteins (Proteins, Gene)FDA Link 01/2024 - 04/2006
14	NivolumabIBA 01/2023 - 09/2015
13	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 04/2010
12	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2004
11	AntigensIBA 01/2023 - 09/2004
9	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2023 - 01/2017
9	CilengitideIBA 05/2018 - 08/2008
8	Angiogenesis InhibitorsIBA 11/2023 - 04/2010
8	Phosphotransferases (Kinase)IBA 11/2019 - 01/2005
8	IntegrinsIBA 05/2018 - 08/2008
7	RNA (Ribonucleic Acid)IBA 12/2023 - 03/2015
7	TOR Serine-Threonine KinasesIBA 11/2019 - 01/2005
7	Carmustine (FIVB)FDA Link 11/2014 - 05/2002
6	IpilimumabIBA 12/2021 - 09/2015
6	pembrolizumabIBA 01/2021 - 09/2015
6	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 01/2005
6	EnzymesIBA 02/2013 - 02/2006
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2012 - 01/2010
6	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 12/2005
6	O(6)-benzylguanineIBA 10/2009 - 05/2002
5	MethyltransferasesIBA 09/2023 - 08/2013
5	InterferonsIBA 01/2023 - 01/2018
5	B7-H1 AntigenIBA 01/2022 - 03/2015
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2017
5	DNA (Deoxyribonucleic Acid)IBA 05/2018 - 05/2008
5	Anticonvulsants (Antiepileptic Drugs)IBA 03/2016 - 02/2006
5	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2012 - 12/2005
5	Peptides (Polypeptides)IBA 01/2012 - 05/2008
4	Sirolimus (Rapamycin)FDA Link 01/2023 - 02/2006
4	SteroidsIBA 01/2023 - 01/2005
4	Lomustine (CCNU)FDA Link 05/2022 - 11/2014
4	LigandsIBA 01/2021 - 02/2016
4	CytokinesIBA 01/2021 - 01/2012
4	AntibodiesIBA 10/2018 - 02/2016
4	cabozantinibIBA 01/2018 - 02/2016
4	Cytotoxins (Cytolysins)IBA 11/2015 - 02/2007
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2012 - 11/2005
4	Immunotoxins (Immunotoxin)IBA 09/2011 - 01/2005
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2023 - 07/2012
3	Protein Subunit VaccinesIBA 01/2023 - 11/2010
3	AfatinibIBA 01/2022 - 03/2015
3	rindopepimutIBA 01/2020 - 01/2015
3	depatuxizumab mafodotinIBA 01/2019 - 12/2017
3	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 07/2017
3	EpitopesIBA 01/2019 - 01/2018
3	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 12/2011
3	Messenger RNA (mRNA)IBA 11/2016 - 04/2006
3	O(6)-Methylguanine-DNA MethyltransferaseIBA 05/2015 - 05/2002
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015 - 02/2006
3	Alkylating AgentsIBA 08/2013 - 05/2003
3	AEE 788 (AEE788)IBA 06/2012 - 01/2005
3	Adenosine Triphosphate (ATP)IBA 05/2012 - 12/2005
3	Everolimus FDA Link 01/2012 - 01/2005
3	Human Serum Albumin FDA LinkGeneric 09/2011 - 03/2007
3	Topoisomerase I InhibitorsIBA 10/2005 - 04/2004
2	Hormones (Hormone)IBA 10/2023 - 06/2016

Therapy/Procedure

118	Therapeutics 12/2023 - 01/2005
50	Immunotherapy 01/2024 - 09/2004
44	Radiotherapy 11/2023 - 06/2005
33	Drug Therapy (Chemotherapy) 10/2023 - 04/2003
7	Chemoradiotherapy 11/2022 - 04/2010
7	Salvage Therapy 10/2018 - 02/2007
4	Re-Irradiation 01/2024 - 07/2016
4	Radioimmunotherapy 05/2007 - 09/2005
3	Molecular Targeted Therapy 01/2021 - 02/2015
3	Drug Tapering 01/2018 - 01/2012
3	Brachytherapy 09/2015 - 01/2006